CAMPBELL, Calif., Aug. 28, 2019 /PRNewswire/ — VivaLNK, a leading provider of connected healthcare solutions, announces an agreement to provide its medical wearable ECG sensors to Emory University for a study to evaluate autonomic function in predicting coronary artery disease (CAD) and its relationship to depression and long-term outcomes. The study builds upon previous work by Emory researchers titled Circadian Autonomic Inflexibility: A Marker of Ischemic Heart Disease, which associates lower heart rate variability (HRV) with subclinical myocardial ischemia.
The VivaLNK medical wearable ECG patch contains an electrocardiography sensor and accelerometer to capture and generate multiple physiological data including ECG trace, heart rate, RR-interval, and 3-axis motion. About the size of a small bandage, the reusable and rechargeable patch weighs a mere 7.5 grams, and can be worn continuously for 72 hours at-a-time to capture and transmit data in real time.
“VivaLNK’s ECG patch is very small and comfortable to wear, which are important factors for clinical use and long-term ECG monitoring,” said Amit Shah, MD, Assistant Professor of Epidemiology at the Rollins School of Public Health at Emory University. “In addition, the software development kit makes it easy to use the patch for research and product development purposes.”
As part of the study, the device will be used to remotely monitor patients who are undergoing coronary angiography, in order to measure autonomic function. Participants will be monitored using the ECG patch for continuous 72-hour periods in a clinical and ambulatory environment, which offers a more complete picture in a natural setting. The research goal is to better understand the role of the autonomic nervous system in depression and coronary artery disease, and to develop better tools for clinical assessment.
For more information on the VivaLNK ECG Patch visit: https://www.vivalnk.com/ecg-monitor.
About VivaLNK
VivaLNK is a provider of connected healthcare solutions for wellness, patient care, and telemedicine. The company’s portfolio includes wearable medical grade devices and data analytics applications that continuously monitor the health and well-being of individuals. The company’s vision is to improve the quality and accessibility of healthcare worldwide by combining technology, data, and analytics into an integrated solution.
Media Contact:
pr@VivaLNK.com
View original content:http://www.prnewswire.com/news-releases/vivalnks-wearable-ecg-patch-used-in-study-of-autonomic-function-in-predicting-heart-disease-300907984.html
SOURCE VivaLNK
MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…
New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…
TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…
Open-source leader democratizes enterprise-grade secrets management for fastest-growing startups, Fortune 500 enterprises, and nation-states. SAN…
MIAMI, June 6, 2025 /PRNewswire/ -- Healthy Together, a leading provider of health and human…
Fifth expansion since 2020 reflects growing demand for advanced pharmaceutical analysis and development services. WEST…